A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C

By K. Lindsay, C. Trépo, T. Heintges, M. Shiffman, S. Gordon, J. Hoefs, E. Schiff, Z. Goodman, M. Laughlin, R. Yao and 1 more. Hepatology, 2001

654 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/e24b5554987e3325b30e88fffd23e0999c07f5a0

Citations in the corpus

• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. (2002, neutral): “Adverse event 48 (11) 95 (21) 47 ( 11 ) 97 (22) 14 (6) 39 (17) Laboratory abnormality”